Health Canada released guidance to drug manufacturers, importers and other market authorization holders on providing foreign regulatory action safety information. The intended outcome is that the Minister will have early knowledge of regulatory actions that are taken in foreign jurisdictions to assess risks to Canadians and to take appropriate action to mitigate those risks when warranted.
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
